Philadelphia Inquirer (Free subscription) | 29/08/2008
Advertisements appearing this week that attack GlaxoSmithKline P.L.C. don't beat around the bush: "DON'T BE FOOLED: GlaxoSmithKline's scare tactics are only concerned with protecting its profit, not the health of people with HIV/AIDS," the ads read.
Philadelphia Inquirer (Free subscription) | 25/08/2008
GlaxoSmithKline P.L.C.'s recently appointed chief executive, Andrew Witty, found lots of inspiration as he ran the London Marathon in April.
GuruFocus Updates (Free subscription) | 15/08/2008
While a lot of value investors got hurt with the recent downturn, Bruce Berkowitz did well by owning energy stocks and not owning financials. Now the "Ignore the Crowd" guru is reducing energy holdings and invest heavily into healthcare stocks. These are his buys and sells during the second quarter.
Business Wire (Free subscription) | 14/08/2008
Business Wire (Free subscription) | 12/08/2008
CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting
The Boston Business Journal (Free subscription) | 06/08/2008
Tolerx Inc. has begun a late-stage human clinical trial for a new diabetes treatment. As a result, development partner GlaxoSmithKline PLC will give the company a $15 million milestone payment. (GSK)
Philadelphia Inquirer (Free subscription) | 01/08/2008
NEW YORK - When it comes to picking new drugs, big pharmaceutical companies behave like parents asked to judge their own offspring, said Andrew Witty, the new chief executive officer of GlaxoSmithKline P.L.C.
IPBiz (Free subscription) | 31/07/2008
Bloomberg reports on 31 July: Daiichi Sankyo Co.'s longer-acting version of GlaxoSmithKline Plc's flu drug, Relenza, was as effective as a course of Tamiflu, a patient study found. The safety and efficacy of a single dose of the inhaled medicine was ``statistically indistinguishable'' from a twice-a- day dose of Roche Holding AG's Tamiflu taken for five days, said Melbourne-based Biota Holdings Ltd.,...
H5N1 (Free subscription) | 31/07/2008
Via Bloomberg: Longer-acting Relenza fights flu as well as Tamiflu, study says. Excerpt: Daiichi Sankyo Co.'s longer-acting version of GlaxoSmithKline Plc's flu drug, Relenza, was as effective as a course of Tamiflu, a patient study found. The safety and efficacy...
Reuters (Free subscription) | 30/07/2008
NEW YORK (Reuters) - The new chief executive of GlaxoSmithKline Plc said on Wednesday therapeutic vaccines used to treat cancer and other diseases could become a major product line for the world's second-largest drugmaker.
MSNBC.com (Free subscription) | 25/07/2008
AIDS patients should have a genetic test before treatment with GlaxoSmithKline Plc's drug Ziagen to see whether they face a higher risk of a potentially fatal reaction, U.S. regulators said on Thursday.
Reuters UK (Free subscription) | 24/07/2008
WASHINGTON (Reuters) - AIDS patients should be given a genetic test before treatment with GlaxoSmithKline Plc's drug, Ziagen, to see if they face a higher risk of a potentially fatal reaction, U.S. regulators said on Thursday.
Reuters (Free subscription) | 24/07/2008
WASHINGTON (Reuters) - AIDS patients should be tested before treatment with GlaxoSmithKline Plc's AIDS drug Ziagen for a genetic variant that raises the risk of a potentially fatal reaction, U.S. regulators said on Thursday.
The Boston Business Journal (Free subscription) | 24/07/2008
The Harvard Stem Cell Institute will be getting at least $25 million from GlaxoSmithKline Plc. over the next few years to focus on new-drug development. (GSK)
Market Watch (Free subscription) | 24/07/2008
BOSTON (MarketWatch) -- Drug stocks slipped modestly in early trading Thursday as shares of GlaxoSmithKline PLC fell the day after it announced its new strategy for jump-starting profits. The Amex Pharmaceutical Index was virtually flat at 304.7 and the Amex Biotechnology Index dipped 0.6% to 827.3. Glaxo shares dropped 3% to $47.36. On Wednesday, Glaxo announced that it plans to move away from developing...
